Search Results
Ch. 6: FREEDOM-2 Phase 2 Trial with FCR001, Designed to Induce Immune Tolerance in LDKT Recipients
FREEDOM-1: A New Frontier in Living Donor Kidney Transplant
Talaris Therapeutics’ Presentation for the Alport Syndrome Foundation Webinar
Talaris Presentation at the 2022 Tandem Transplantation and Cellular Therapy Meeting
Talaris Presentation at the 2022 Cutting Edge of Transplantation (CEoT) Transplant Summit
Innovation in Kidney Transplantation and Post-care (Talaris Therapeutics)
